Alzheimer’s Prevention Trials—The Future Looks Promising

Alzheimer’s Prevention Trials—The Future Looks Promising

While there is active research for more effective disease-modifying drugs* the lack of any significant breakthroughs in the treatment of the Alzheimer’s disease has propelled a paradigm shift away from focusing solely on a drug solution, to an inclusive prevention model that emphasizes risk reduction and prevention, which promises to attenuate the portentous global burden incurred by the disease.

Current prevalence estimates (2016) for late-onset Alzheimer’s disease (LOAD) in the United States (U.S.) is approximately 5.1 million.(1) By 2050 the projected prevalence of LOAD is expected to escalate to 13.8 million and a staggering 106.8 million worldwide.(2,3) Pharmacological treatments for LOAD such as cholinesterase inhibitors and NMDA receptor antagonists may slow its progression or attenuate specific molecular pathomechanisms associated with the disease process, but are not long term solutions or curative.

MEMBER ACCESS: Mild Cognitive Impairment (MCI)—Telltale Signs That You May Be At Increased Risk for Dementia or Alzheimer’s Disease

By Ralph Sanchez, L.Ac.,CNS,D.Hom

Long before a diagnosis of dementia or Alzheimers disease (AD) ...

Members Only

This is member access content and is available with a free Brainy member registration.

If you have already registered, please login below.

If you have not setup your free lifetime membership you can learn more and register for access along with my newsletter here.


Pin It on Pinterest